Abstract
The macrocyclic lactone endectocides typified by ivermectin are safe and effective drugs when used according to label directions. However, off-label use, misuse and overdosing can result in toxicity in animal patients as revealed by pharmacovigilance activities. Preclinical toxicity studies demonstrates that the major clinical signs of toxicity are those associated with neurotoxic effects and these are the most common adverse drug reactions noted in overdosed treated animals. Subpopulations of some strains or breeds of some species appear to be uniquely sensitive to the neurotoxic effects of the macrocyclic lactones due to enhanced brain penetration by these drugs as a result of a deficiency in P-glycoprotein arising as a result of a mutation in the MDR1 gene.
Keywords: Avermectins, ivermectin, macrocyclic lactones, milbemycins, moxidectin, neurotoxicity, P-glycoprotein, pharmacovigilance
Current Pharmaceutical Biotechnology
Title:Toxicity in Animals: Target Species
Volume: 13 Issue: 6
Author(s): K. N. Woodward
Affiliation:
Keywords: Avermectins, ivermectin, macrocyclic lactones, milbemycins, moxidectin, neurotoxicity, P-glycoprotein, pharmacovigilance
Abstract: The macrocyclic lactone endectocides typified by ivermectin are safe and effective drugs when used according to label directions. However, off-label use, misuse and overdosing can result in toxicity in animal patients as revealed by pharmacovigilance activities. Preclinical toxicity studies demonstrates that the major clinical signs of toxicity are those associated with neurotoxic effects and these are the most common adverse drug reactions noted in overdosed treated animals. Subpopulations of some strains or breeds of some species appear to be uniquely sensitive to the neurotoxic effects of the macrocyclic lactones due to enhanced brain penetration by these drugs as a result of a deficiency in P-glycoprotein arising as a result of a mutation in the MDR1 gene.
Export Options
About this article
Cite this article as:
N. Woodward K., Toxicity in Animals: Target Species, Current Pharmaceutical Biotechnology 2012; 13 (6) . https://dx.doi.org/10.2174/138920112800399176
DOI https://dx.doi.org/10.2174/138920112800399176 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers